Challenges in Adjudicating Endpoints for Kidney Disease

In the endpoint adjudication space the gold standard for the review of clinical outcomes is to have standardized universal event definitions. Although there have been multiple global kidney outcome trials in the past 10 years, there is currently no such universal definition for End Stage Kidney Disease. In addition to this, the adjudication of kidney endpoints still faces many clinical, practical and regional challenges. In this interactive webinar, our CMO Dr. Maria Ali will discuss this topic with leading nephrologists Prof. Dan Weiner and Prof. Stephen Seliger to gather their perspectives on these issues and the latest thinking on approaches to address them.

What is discussed:
– How kidney outcomes are currently adjudicated
– Successful aspects of kidney event adjudication
– Current challenges in adjudication of kidney events
– Design attributes to be considered for kidney outcome trials
– Subsets of kidney disease patients that should be considered
– Identifying non-kidney events in patients with very advanced kidney disease
– Where adjudication of kidney endpoints is heading in the future